Two single-nucleotide polymorphisms in the 5′ and 3′ ends of the osteopontin gene contribute to susceptibility to systemic lupus erythematosus

Arthritis and Rheumatism

Volumn 52, Issue 2, 2005, Pages 539-547

  D'Alfonso, S ^a   Barizzone, N ^a   Giordano, M ^a   Chiocchetti, A ^a   Magnani, C ^a   Castelli, L ^a   Indelicato, M ^a,b   Giacopelli, F ^c   Marchini, M ^d   Scorza, R ^d   Danieli, M G ^e   Cappelli, M ^e   Migliaresi, S ^f   Bigliardo, B ^f   Sabbadini, M G ^g,h   Baldissera, E ^g,h   Galeazzi, M ⁱ   Sebastiani, G D ^j   Minisola, G ^j   Ravazzolo, R ^c,k   Dianzani, U ^a   Momigliano Richiardi, P ^a   more..

^a UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c G GASLINI INSTITUTE   (Italy)

^d UNIVERSITY OF MILAN   (Italy)

^e UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^f SECOND UNIVERSITY OF NAPLES   (Italy)

^g VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^h SAN RAFFAELE HOSPITAL   (Italy)

ⁱ UNIVERSITY OF SIENA   (Italy)

^j SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^k UNIVERSITY OF GENOA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DNA; OSTEOPONTIN;

ADULT; ALLELE; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DNA FLANKING REGION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; LYMPH NODE HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMIC LUPUS ERYTHEMATOSUS;

DISEASE SUSCEPTIBILITY; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OSTEOPONTIN; POLYMORPHISM, SINGLE NUCLEOTIDE; SIALOGLYCOPROTEINS;

EID: 13444253766     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.20808     Document Type: Article

References (41)

1. O'Regan A, Herman JS. Osteopontin: a key cytokine in cell-mediated and granulomatous inflammation. Int J Exp Pathol 2000;81:373-90.
2. Denhardt DT, Noda M, O'Regan AW, Pavlin D, Herman JS. Osteopontin as a means to cope with environmental insults: regulation of inflammation, tissue remodeling, and cell survival. J Clin Invest 2001;107:1055-61.
3. O'Regan AW, Nau GJ, Chupp GL, Herman JS. Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 2000;21:475-8.
4. Ashkar S, Weber GF, Panoutsakopoulou V, Sanchirico ME, Jansson M, Zawaideh S, et al. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 2000;287:860-4.
5. O'Regan AW, Hayden JM, Herman JS. Osteopontin augments CD3-mediated interferon-γ and CD40 ligand expression by T cells, which results in IL-12 production from peripheral blood mononuclear cells. J Leukoc Biol 2000;68:495-502.
6. Iizuka J, Katagiri Y, Tada N, Murakami M, Ikeda T, Sato M, et al. Introduction of an osteopontin gene confers the increase in B1 cell population and the production of anti-DNA autoantibodies. Lab Invest 1998;78:1523-33.
7. Katagiri Y, Mori K, Hara T, Tanaka K, Murakami M, Uede T. Functional analysis of the osteopontin molecule. Ann N Y Acad Sci 1995;760:371-4.
8. Okada H, Moriwaki K, Konishi K, Kobayashi T, Sugahara S, Nakamoto H, et al. Tubular osteopontin expression in human glomerulonephritis and renal vasculitis. Am J Kidney Dis 2000;36:498-506.
9. Masutani K, Akahoshi M, Tsuruya K, Tokumoto M, Ninomiya T, Kohsaka T, et al. Predominance of Th1 immune response in diffuse proliferative lupus nephritis. Arthritis Rheum 2001;44:2097-106
10. Forton AC, Petri MA, Goldman D, Sullivan KE. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum Mutat 2002;19:459-62.
11. Patarca R, Wei FY, Singh P, Morasso MI, Cantor H. Dysregulated expression of the T cell cytokine Eta-1 in CD4-8-lymphocytes during the development of murine autoimmune disease. J Exp Med 1990;172:1177-83.
12. Lampe MA, Patarca R, Iregui MV, Cantor H. Polyclonal B cell activation by the Eta-1 cytokine and the development of systemic autoimmune disease. J Immunol 1991;147:2902-6.
13. Weber GF, Cantor H. Differential roles of osteopontin/Eta-1 in early and late lpr disease. Clin Exp Immunol 2001;126:578-83.
14. Wuthrich RP, Fan X, Ritthaler T, Sibalic V, Yu DJ, Loffing J, et al. Enhanced osteopontin expression and macrophage infiltration in MRL-Fas(1pr) mice with lupus nephritis. Autoimmunity 1998;28:139-50.
15. Chiocchetti A, Indelicato M, Bensi T, Mesturini R, Giordano M, Sametti S, et al. High levels of osteopontin associated with polymorphisms in its gene are a risk factor for development of autoimmunity/lymphoproliferation. Blood 2004;103:1376-82.
16. Fisher GH, Rosenberg FJ, Straus SE, Dale JK, Middleton LA, Lin AY, et al. Dominant interfering Fas gene mutations impair apoptosis in a human autoimmune lymphoproliferative syndrome. Cell 1995;81:935-46.
17. Nagata S. Apoptosis by death factor. Cell 1997;88:355-65.
18. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus [letter]. Arthritis Rheum 1997;40:1725.
19. D'Alfonso S, Giordano M, Mellai M, Lanceni M, Barizzone N, Marchini M, et al. Association tests with systemic lupus erythematosus of IL10 markers indicate a direct involvement of a CA repeat in the 5′ regulatory region. Genes Immun 2002;3:454-63.
20. Jones AC, Austin J, Hansen N, Hoogendoorn B, Oefner PJ, Cheadle JP, et al. Optimal temperature selection for mutation detection by denaturing HPLC and comparison to single-stranded conformation polymorphism and heteroduplex analysis. Clin Chem 1999;45:1133-40.
21. Hoogendoorn B, Owen MJ, Oefner PJ, Williams N, Austin J, O'Donovan MC. Genotyping single nucleotide polymorphisms by primer extension and high performance liquid chromatography. Hum Genet 1999;104:89-93.
22. Schneider S, Kueffer JM, Roessli D, Excoffier L. Arlequin version 1.1: a software for population genetic data analysis. Switzerland: Genetics and Biometry Laboratory, University of Geneva; 1997.
23. Lewontin RC. The interaction of selection and linkage. 1. General consideration: heterotic models. Genetics 1964;49:49-67.
24. Pritchard JK, Przeworski M. Linkage disequilibrium in humans: models and data. Am J Hum Genet 2001;69:1-14.
25. Breslow NE, Day NE. Statistical methods in cancer research. Vol 1. The analysis of case-control studies. Lyon: IARC Scientific Publications; 1980.
26. Hosmer D, Lemeshow S. Confidence interval estimation of interaction. Epidemiology 1992;3:452-6.
27. Kleinbaum DG, Kupper LL, Morgenstern H. Epidemiologic research principles and quantitative methods. New York: Van Nostrand Reinhold; 1982. p. 448-51.
28. Mochida S, Hashimoto M, Matsui A, Naito M, Inao M, Nagoshi S, et al. Genetic polymorphisms in promoter region of osteopontin gene may be a marker reflecting hepatitis activity in chronic hepatitis C patients. Biochem Biophys Res Commun 2004;313:1079-85.
29. Iwasaki H, Shinohara Y, Ezura Y, Ishida R, Kodaira M, Kajita M, et al. Thirteen single-nucleotide polymorphisms in the human osteopontin gene identified by sequencing of the entire gene in Japanese individuals. J Hum Genet 2001;46:544-6.
30. Giacopelli F, Rosatto N, Divizia MT, Cusano R, Caridi G, Ravazzolo R. The first intron of the human osteopontin gene contains a C/EBP-β-responsive enhancer. Gene Expr 2003;11:95-104.
31. Jannot AS, Essioux L, Reese MG, Clerget-Darpoux F. Improved use of SNP information to detect the role of genes. Genet Epidemiol 2003;25:158-67.
32. Tahri-Daizadeh N, Tregouet DA, Nicaud V, Manuel N, Cambien F, Tiret L. Automated detection of informative combined effects in genetic association studies of complex traits. Genome Res 2003;13:1952-60.
33. Giacopelli F, Marciano R, Pistorio A, Catarsi P, Canini S, Karsenty G, et al. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics 2004. Epub ahead of print.
34. Alarcon-Riquelme ME. A RUNX trio with a taste for autoimmunity. Nat Genet 2003;35:299-300.
35. Cartegni L, Chew SL, Krainer AR. Listening to silence and understanding nonsense: exonic mutations that affect splicing. Nat Rev Genet 2002;3:285-98.
36. Kon S, Maeda M, Segawa T, Hagiwara Y, Horikoshi Y, Chikuma S, et al. Antibodies to different peptides in osteopontin reveal complexities in the various secreted forms. J Cell Biochem 2000;77:487-98.
37. Mazumder B, Seshadri V, Fox PL. Translational control by the 3′-UTR: the ends specify the means. Trends Biochem Sci 2003;28:91-8.
38. Conne B, Stutz A, Vassalli JD. The 3′ untranslated region of messenger RNA: a molecular 'hotspot' for pathology? Nat Med 2000;6:637-41.
39. Mendell JT, Dietz HC. When the message goes awry: disease-producing mutations that influence mRNA content and performance. Cell 2001;107:411-4.
40. Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, et al. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science 1994;263:1759-62.
41. Lin YH, Yang-Yen HF. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol 3-kinase/Akt signaling pathway. J Biol Chem 2001;276:46024-30.